News | Breast Density | June 28, 2017

New Study Highlights Breakthrough Therapy to Reduce Mammographic Breast Density

Therapy combining testosterone and aromatase inhibitor found to reduce fibroglandular breast density by nearly 20 percent

New Study Highlights Breakthrough Therapy to Reduce Mammographic Breast Density

June 26, 2017 — Stephen N. Birrell, M.D., Ph.D., presented breakthrough findings into the reduction of mammographic breast density at the 8th International Breast Densitometry and Cancer Risk Assessment Conference in San Francisco. The conference, co-chaired by University of California San Francisco and Karolinska Institutet, included presentations and posters by researchers from institutions across the world, including the Mayo Clinic and Queen Mary University of London.

Birrell, chief medical officer of HAVAH Therapeutics, undertook a study to examine the effect of the company's T+Ai (testosterone plus aromatase inhibitor) therapy that intends to mimic the effects of tamoxifen by reducing mammographic breast density in pre-menopausal women without perturbations in hypothalamic-pituitary function. One hundred and fifty women undergoing mammographic screening and having high mammographic breast density as determined by a percent volumetric breast density (%VBD) measurement of equal to or greater than 15.5 VBD as measured by Volpara, were randomly chosen for inclusion in the study. A VBD of 15.5 percent is equivalent to a BI-RADS D classification.

The participants were allocated in a non-randomized fashion to either (a) follow-up mammography at 1 year for mammographic breast density calculation or (b) treatment with a subcutaneous pellet of testosterone (60-100 mg) and anastrozole (1-3mg) (dependent on BMI) every 4 months plus a follow-up mammogram for mammographic breast density calculation at 1 year. There were no significant differences in the base-line characteristics of each cohort. Hormone levels were evaluated every 4 months and follicular stimulating (FSH) and luteinizing hormones (LH) were compared from baseline to the same stage of each woman's menstrual cycle 3 months later. Serum anastrozole levels were measured at 1 and 4 months after treatment was commenced.

Seventy-four women were included in the cohort study (2 lost in pre-screening). None were lost to follow-up during the study period. There was a small (2 percent) reduction in mean %VBD in the control group compared to the treatment cohort (19.5 percent). There was no significant change in either FSH or LH. There were no serious adverse events and no androgenicity events resulting in cessation of treatment.

In conclusion, testosterone combined with anastrozole is an effective method of reducing high mammographic breast density in pre-menopausal women. This is achieved by manipulating the amplified hormone catalytic enzymatic system of high mammographic breast density tissue to effect an alteration in the breast tissue estrogen to testosterone ratio; thus inducing a state of breast tissue involution commensurate with that occurring with tamoxifen chemoprevention. This was achieved with excellent tolerance and no adverse effect on hypothalamic-pituitary function.

Birrell's cohort study results were supported by a poster presentation regarding a secondary study on the effect of T+Ai in reducing breast tissue stiffness and breast pain in a cohort of 10 women. A clear signal was observed with all women experiencing a reduction in tissue stiffness and pain of 53 percent and 67 percent, respectively.

For more information: www.havahtherapeutics.com

Related Content

Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Smartphone Addiction Creates Imbalance in Brain
News | Mobile Devices | January 11, 2018
Researchers have found an imbalance in the brain chemistry of young people addicted to smartphones and the internet,...
Fat Distribution in Women and Men Provides Clues to Heart Attack Risk
News | Women's Health | January 11, 2018
January 11, 2018 – It’s not the amount of fat in your body but where it is stored that may increase your risk for hea
Minimally Invasive Treatment Provides Relief from Back Pain

Lumbar spine MRI showing disc herniation and nerve root at baseline and one month after treatment

News | Interventional Radiology | January 11, 2018
The majority of patients were pain free after receiving a new image-guided pulsed radiofrequency treatment for low back...
Emergency Radiologists See Inner Toll of Opioid Use Disorders

Rates of Imaging Positivity for IV-SUDs Complications. Image courtesy of Efren J. Flores, M.D.

News | Clinical Study | January 11, 2018
January 11, 2018 – Emergency radiologists are seeing a high prevalence of patients with complications related to opio
CT Shows Enlarged Aortas in Former Pro Football Players

3-D rendering from a cardiac CT dataset demonstrating mild dilation of the ascending aorta.

News | Computed Tomography (CT) | January 11, 2018
Former National Football League (NFL) players are more likely to have enlarged aortas, a condition that may put them at...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec

Size comparison between 3-D printed prosthesis implant and a penny.

News | 3-D Printing | January 11, 2018
January 11, 2018 — Researchers using...
RSNA 2017 technical exhibits, expo floor, showing new radiology technology advances.
Feature | RSNA 2017 | January 11, 2018
January 11, 2018 — Here is a list of some of the key clinical study presentations, articles on trends and videos from
Hip Steroid Injections Associated with Bone Changes

58-year-old woman with left hip pain. X-ray from one month prior to the steroid/anesthetic injection demonstrates moderate joint space narrowing (arrows) and bony proliferation (arrowheads).

News | Orthopedic Imaging | January 11, 2018
January 11, 2018 – Osteoarthritis patients who received a steroid injection in the hip had a significantly greater in
Overlay Init